Mineralys Therapeutics publishes corporate presentation on lorundrostat for uncontrolled, resistant hypertension and cardiorenal diseases
MLYS•Corporate presentation highlights lorundrostat data and FDA filing
Mineralys Therapeutics publishes corporate presentation on lorundrostat for uncontrolled, resistant hypertension and cardiorenal diseases
- Mineralys highlighted FDA acceptance of its NDA for lorundrostat, with a PDUFA target date of Dec. 22, 2026.
- Lorundrostat is positioned as a once-daily selective aldosterone synthase inhibitor for uncontrolled or resistant hypertension, targeting dysregulated aldosterone.
- Pivotal data showed placebo-adjusted systolic blood pressure reductions of 11.6 mmHg at week 6 and 7.9 mmHg at week 12.
- Proof-of-concept studies showed benefit in hypertension patients with chronic kidney disease, including a 31% UACR reduction at 4 weeks.
- Cash balance was USD 661 million at June 30, 2026; common shares outstanding totaled 88,956,640 as of Aug. 3, 2026.
